Bavarian Nordic and Serum Institute of India Expand Strategic Partnership with Chikungunya Vaccine Manufacturing Agreement

AI Briefing

• – Bavarian Nordic and Serum Institute of India expand partnership to manufacture chikungunya vaccine, boost capacity for low- and middle-income countries.
• – Agreement covers full tech transfer of manufacturing process for chikungunya vaccine (CHIKV VLP) from Bavarian Nordic to Serum Institute of India.
• – Expansion builds on existing mpox vaccine license and manufacturing agreement with Serum Institute of India, replacing previous agreement with Biological E. Limited.